Cardiorenal syndrome in hypertensive rats: Microalbuminuria, inflammation and ventricular hypertrophy

Physiological Research

Volumn 61, Issue 1, 2012, Pages 13-24

  Moubarak, M ^a   Jabbour, H ^a   Smayra, V ^a   Chouery, E ^a   Saliba, Y ^a   Jebara, V ^a   Fares N ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Inflammation; Left ventricular hypertrophy; Microalbuminuria

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANIMAL; ARTICLE; BLOOD PRESSURE; CARDIORENAL SYNDROME; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; INFLAMMATION; MALE; METABOLISM; PHYSIOLOGY; RAT; WISTAR RAT;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIO-RENAL SYNDROME; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; INTERLEUKIN-6; MALE; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861541177     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. ARNLOV J, EVANS JC, MEIGS JB, WANG TJ, FOX CS, LEVY D, BENJAMIN EJ, D'AGOSTINO RB, VASAN RS: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112: 969-975, 2005.
2. ASSADI F: Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol 28: 27-33, 2007.
3. ASSADI F: Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr Cardiol 29: 580-584, 2008.
4. BAHRAMI H, BLUEMKE DA, KRONMAL R, BERTONI AG, LLOYD-JONES DM, SHAHAR E, SZKLO M, LIMA JA: Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51: 1775-1783, 2008.
5. BASI S, LEWIS JB: Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 47: 927-946, 2006.
6. BAUTISTA LE, VERA LM, ARENAS IA, GAMARRA G: Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 19: 149-154, 2005.
7. BERTON G, CORDIANO R, MAZZUCO S, KATZ E, DE TONI R, PALATINI P: Albumin excretion in acute myocardial infarction: a guide for long-term prognosis. Am Heart J 156: 760-768, 2008.
8. BILOUS R, CHATURVEDI N, SJOLIE AK, FULLER J, KLEIN R, ORCHARD T, PORTA M, PARVING HH: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 151: 11-20, W3-W4, 2009.
9. BLAKE GJ, RIDKER PM: C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 41: 37S-42S, 2003.
10. BRANTSMA AH, BAKKER SJ, DE ZEEUW D, DE JONG PE, GANSEVOORT RT: Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol 17: 331-335, 2006.
11. BRANTSMA AH, BAKKER SJ, HILLEGE HL, DE ZEEUW D, DE JONG PE, GANSEVOORT RT: Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28: 2525-2530, 2005.
12. CARR AA, KOWEY PR, DEVEREUX RB, BRENNER BM, DAHLOF B, IBSEN H, LINDHOLM LH, LYLE PA, SNAPINN SM, ZHANG Z, EDELMAN JM, SHAHINFAR S: Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 96: 1530-1536, 2005.
13. CLAUSEN P, JENSEN JS, JENSEN G, BORCH-JOHNSEN K, FELDT-RASMUSSEN B: Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 103: 1869-1874, 2001.
14. DE ZEEUW D, PARVING HH, HENNING RH: Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 17: 2100-2105, 2006.
15. DE ZEEUW D, REMUZZI G, PARVING HH, KEANE WF, ZHANG Z, SHAHINFAR S, SNAPINN S, COOPER ME, MITCH WE, BRENNER BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927, 2004.
16. DJOUSSE L, KOCHAR J, HUNT SC, NORTH KE, GU CC, TANG W, ARNETT DK, DEVEREUX RB: Relation of albuminuria to left ventricular mass (from the HyperGEN Study). Am J Cardiol 101: 212-216, 2008.
17. FARES N, GOMEZ JP, POTREAU D: T-type calcium current is expressed in dedifferentiated adult rat ventricular cells in primary culture. C R Acad Sci III 319: 569-576, 1996.
18. FESTA A, D'AGOSTINO R, HOWARD G, MYKKANEN L, TRACY RP, HAFFNER SM: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 58: 1703-1710, 2000.
19. FISMAN EZ, BENDERLY M, ESPER RJ, BEHAR S, BOYKO V, ADLER Y, TANNE D, MATAS Z, TENENBAUM A: Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol 98: 14-18, 2006.
20. FORMAN JP, FISHER ND, SCHOPICK EL, CURHAN GC: Higher levels of albuminuria within the normal range predict incident hypertension. J Am Soc Nephrol 19: 1983-1988, 2008.
21. GUAN H, WANG P, HUI R, EDIN ML, ZELDIN DC, WANG DW: Adeno-associated virus-mediated human Creactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem 55: 274-284, 2009.
22. HALLAN SI, RITZ E, LYDERSEN S, ROMUNDSTAD S, KVENILD K, ORTH SR: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 20: 1069-1077, 2009.
23. HALLER H, ITO S, IZZO JL Jr, JANUSZEWICZ A, KATAYAMA S, MENNE J, MIMRAN A, RABELINK TJ, RITZ E, RUILOPE LM, RUMP LC, VIBERTI G: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364: 907-917, 2011.
24. HARALDSSON B, NYSTROM J, DEEN WM: Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88: 451-487, 2008.
25. HAUGEN E, TANG MS, ISIC A, ANDERSSON B, FU M: TNFalpha antagonist upregulates interleukin-6 in rats with hypertensive heart failure. Int J Cardiol 130: 64-68, 2008.
26. HEMMELGARN BR, MANNS BJ, LLOYD A, JAMES MT, KLARENBACH S, QUINN RR, WIEBE N, TONELLI M: Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303: 423-429, 2010.
27. HEYWOOD JT: The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9: 195-201, 2004.
28. IBSEN H, OLSEN MH, WACHTELL K, BORCH-JOHNSEN K, LINDHOLM LH, MOGENSEN CE, DAHLOF B, DEVEREUX RB, DE FAIRE U, FYHRQUIST F, JULIUS S, KJELDSEN SE, LEDERBALLE-PEDERSEN O, NIEMINEN MS, OMVIK P, OPARIL S, WAN Y: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45: 198-202, 2005.
29. IBSEN H, OLSEN MH, WACHTELL K, BORCH-JOHNSEN K, LINDHOLM LH, MOGENSEN CE, DAHLOF B, SNAPINN SM, WAN Y, LYLE PA: Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 29: 595-600, 2006.
30. INGELSSON E, SUNDSTROM J, LIND L, RISERUS U, LARSSON A, BASU S, ARNLOV J: Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J 28: 1739-1745, 2007.
31. JAMES MT, HEMMELGARN BR, TONELLI M: Early recognition and prevention of chronic kidney disease. Lancet 375: 1296-1309, 2010.
32. JULIUS S, NESBITT SD, EGAN BM, WEBER MA, MICHELSON EL, KACIROTI N, BLACK HR, GRIMM RH Jr, MESSERLI FH, OPARIL S, SCHORK MA: Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med 354: 1685-1697, 2006.
33. KAPTOGE S, DI ANGELANTONIO E, LOWE G, PEPYS MB, THOMPSON SG, COLLINS R, DANESH J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375: 132-140, 2010.
34. KISTORP C, RAYMOND I, PEDERSEN F, GUSTAFSSON F, FABER J, HILDEBRANDT P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609-1616, 2005.
35. KNIGHT EL, KRAMER HM, CURHAN GC: High-normal blood pressure and microalbuminuria. Am J Kidney Dis 41: 588-595, 2003.
36. KSHIRSAGAR AV, BOMBACK AS, BANG H, GERBER LM, VUPPUTURI S, SHOHAM DA, MAZUMDAR M, BALLANTYNE CM, PAPARELLO JJ, KLEMMER PJ: Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 101: 401-406, 2008.
37. KUBOTA Y, UMEGAKI K, KAGOTA S, TANAKA N, NAKAMURA K, KUNITOMO M, SHINOZUKA K: Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull 29: 1756-1758, 2006.
38. KUNZ R, FRIEDRICH C, WOLBERS M, MANN JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30-48, 2008.
39. MANCIA G, DE BACKER G, DOMINICZAK A, CIFKOVA R, FAGARD R, GERMANO G, GRASSI G, HEAGERTY AM, KJELDSEN SE, LAURENT S, NARKIEWICZ K, RUILOPE L, RYNKIEWICZ A, SCHMIEDER RE, BOUDIER HA, ZANCHETTI A, VAHANIAN A, CAMM J, DE CATERINA R, DEAN V, DICKSTEIN K, FILIPPATOS G, FUNCK-BRENTANO C, HELLEMANS I, KRISTENSEN SD, MCGREGOR K, SECHTEM U, SILBER S, TENDERA M, WIDIMSKY P, ZAMORANO JL, ERDINE S, KIOWSKI W, AGABITI-ROSEI E, AMBROSIONI E, LINDHOLM LH, VIIGIMAA M, ADAMOPOULOS S, BERTOMEU V, CLEMENT D, FARSANG C, GAITA D, LIP G, MALLION JM, MANOLIS AJ, NILSSON PM, O'BRIEN E, PONIKOWSKI P, REDON J, RUSCHITZKA F, TAMARGO J, VAN ZWIETEN P, WAEBER B, WILLIAMS B: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187, 2007.
40. MARCOVECCHIO ML, GIANNINI C, WIDMER B, DALTON RN, MARTINOTTI S, CHIARELLI F, DUNGER DB: C-reactive protein in relation to the development of microalbuminuria in type 1 diabetes: the Oxford Regional Prospective Study. Diabetes Care 31: 974-976, 2008.
41. MATSUSHITA K, VAN DER VELDE M, ASTOR BC, WOODWARD M, LEVEY AS, DE JONG PE, CORESH J, GANSEVOORT RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375: 2073-2081, 2010.
42. MAUER M, ZINMAN B, GARDINER R, SUISSA S, SINAIKO A, STRAND T, DRUMMOND K, DONNELLY S, GOODYER P, GUBLER MC, KLEIN R: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361: 40-51, 2009.
43. NAGAI T, ANZAI T, KANEKO H, MANO Y, ANZAI A, MAEKAWA Y, TAKAHASHI T, MEGURO T, YOSHIKAWA T, FUKUDA K: C-reactive protein overexpression exacerbates pressure overload-induced cardiac remodeling through enhanced inflammatory response. Hypertension 57: 208-215, 2011.
44. NAKAMURA M, ONODA T, ITAI K, OHSAWA M, SATOU K, SAKAI T, SEGAWA T, SASAKI J, TONARI Y, HIRAMORI K, OKAYAMA A: Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med 43: 919-925, 2004.
45. NAVARRO-GONZALEZ JF, MORA C, MUROS M, JARQUE A, HERRERA H, GARCIA J: Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. J Hypertens 26: 2168-2175, 2008.
46. NAYA M, TSUKAMOTO T, MORITA K, KATOH C, FURUMOTO T, FUJII S, TAMAKI N, TSUTSUI H: Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 30: 541-548, 2007.
47. NISHIDA H, HORIO T, SUZUKI Y, IWASHIMA Y, TOKUDOME T, YOSHIHARA F, NAKAMURA S, KAWANO Y: Interleukin-6 as an independent predictor of future cardiovascular events in high-risk Japanese patients: comparison with C-reactive protein. Cytokine 53: 342-346, 2011.
48. OKIN PM, WACHTELL K, DEVEREUX RB, NIEMINEN MS, OIKARINEN L, VIITASALO M, TOIVONEN L, IBSEN H, OLSEN MH, BORCH-JOHNSEN K, LINDHOLM LH, KJELDSEN SE, JULIUS S, DAHLOF B: Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. Am J Hypertens 21: 273-279, 2008.
49. PAI JK, PISCHON T, MA J, MANSON JE, HANKINSON SE, JOSHIPURA K, CURHAN GC, RIFAI N, CANNUSCIO CC, STAMPFER MJ, RIMM EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610, 2004.
50. PALMIERI V, TRACY RP, ROMAN MJ, LIU JE, BEST LG, BELLA JN, ROBBINS DC, HOWARD BV, DEVEREUX RB: Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 26: 2764-2769, 2003.
51. PARVING HH, LEWIS JB, RAVID M, REMUZZI G, HUNSICKER LG: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69: 2057-2063, 2006.
52. PEDRINELLI R, DELL'OMO G, DI BELLO V, PELLEGRINI G, PUCCI L, DEL PRATO S, PENNO G: Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 24: 2414-2419, 2004.
53. PEETERS AC, NETEA MG, JANSSEN MC, KULLBERG BJ, VAN DER MEER JW, THIEN T: Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 31: 31-36, 2001.
54. PERTICONE F, MAIO R, TRIPEPI G, SCIACQUA A, MALLAMACI F, ZOCCALI C: Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J Nephrol 20 (Suppl 12): S56-S62, 2007.
55. PRAVENEC M, KAJIYA T, ZIDEK V, LANDA V, MLEJNEK P, SIMAKOVA M, SILHAVY J, MALINSKA H, OLIYARNYK O, KAZDOVA L, FAN J, WANG J, KURTZ TW: Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension 57: 731-737, 2011.
56. SABANAYAGAM C, LEE J, SHANKAR A, LIM SC, WONG TY, TAI ES: C-reactive protein and microalbuminuria in a multi-ethnic Asian population. Nephrol Dial Transplant 25: 1167-1172, 2010.
57. SALIBA Y, CHOUERY E, MEGARBANE A, JABBOUR H, FARES N: Microalbuminuria versus brain natriuretic peptide in cardiac hypertrophy of hypertensive rats. Physiol Res 59: 871-880, 2010.
58. SALLES GF, FISZMAN R, CARDOSO CR, MUXFELDT ES: Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 50: 723-728, 2007.
59. SAVOIA C, SCHIFFRIN EL: Reduction of C-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag 3: 975-983, 2007.
60. SESSO HD, BURING JE, RIFAI N, BLAKE GJ, GAZIANO JM, RIDKER PM: C-reactive protein and the risk of developing hypertension. JAMA 290: 2945-2951, 2003.
61. STUVELING EM, BAKKER SJ, HILLEGE HL, BURGERHOF JG, DE JONG PE, GANS RO, DE ZEEUW D: C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 43: 791-796, 2004.
62. SUKHIJA R, ARONOW WS, KAKAR P, GARZA L, SACHDEVA R, SINHA A, MEHTA JL: Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol 98: 279-281, 2006.
63. TRAN LT, MACLEOD KM, MCNEILL JH: Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol Cell Biochem 330: 219-228, 2009.
64. TSIOUFIS C, DIMITRIADIS K, CHATZIS D, VASILIADOU C, TOUSOULIS D, PAPADEMETRIOU V, TOUTOUZAS P, STEFANADIS C, KALLIKAZAROS I: Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 96: 946-951, 2005.
65. TSIOUFIS C, DIMITRIADIS K, STEFANADIS C, KALLIKAZAROS I: The emerging role of subclinical inflammation in hypertension-associated early renal dysfunction: focus on microalbuminuria. Hellenic J Cardiol 47: 361-365, 2006.
66. TSIOUFIS C, DIMITRIADIS K, TAXIARCHOU E, VASILIADOU C, CHARTZOULAKIS G, TOUSOULIS D, MANOLIS A, STEFANADIS C, KALLIKAZAROS I: Diverse associations of microalbuminuria with Creactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 19: 462-466, 2006.
67. TSIOUFIS C, STOUGIANNOS P, KAKKAVAS A, TOUTOUZA M, MARIOLIS A, VLASSEROS I, STEFANADIS C, KALLIKAZAROS I: Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol 96: 252-256, 2005.
68. TZOULAKI I, MURRAY GD, LEE AJ, RUMLEY A, LOWE GD, FOWKES FG: C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112: 976-983, 2005.
69. VAKILI BA, OKIN PM, DEVEREUX RB: Prognostic implications of left ventricular hypertrophy. Am Heart J 141: 334-341, 2001.
70. VENEGAS-PONT M, MANIGRASSO MB, GRIFONI SC, LAMARCA BB, MARIC C, RACUSEN LC, GLOVER PH, JONES AV, DRUMMOND HA, RYAN MJ: Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension 56: 643-649, 2010.
71. VERMA S, LI SH, BADIWALA MV, WEISEL RD, FEDAK PW, LI RK, DHILLON B, MICKLE DA: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105: 1890-1896, 2002a.
72. VERMA S, WANG CH, LI SH, DUMONT AS, FEDAK PW, BADIWALA MV, DHILLON B, WEISEL RD, LI RK, MICKLE DA, STEWART DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919, 2002b.
73. WANG CH, LI SH, WEISEL RD, FEDAK PW, DUMONT AS, SZMITKO P, LI RK, MICKLE DA, VERMA S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107: 1783-1790, 2003.
74. WANG TJ, EVANS JC, MEIGS JB, RIFAI N, FOX CS, D'AGOSTINO RB, LEVY D, VASAN RS: Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 111: 1370-1376, 2005.
75. WELSH P, LOWE GD, CHALMERS J, CAMPBELL DJ, RUMLEY A, NEAL BC, MACMAHON SW, WOODWARD M: Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 39: 2226-2230, 2008.
76. YUYUN MF, KHAW KT, LUBEN R, WELCH A, BINGHAM S, DAY NE, WAREHAM NJ: A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 159: 284-293, 2004.